Difference between revisions of "Sciellin"
m |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
| − | |||
| − | |||
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 47: | Line 45: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Epidermal transglutaminase|*]] | [[Category:Epidermal transglutaminase|*]] | ||
Latest revision as of 12:04, 10 March 2015
| Sciellin | |
|---|---|
| Substrate peptide name | Sciellin |
| Synonyms | |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cornified envelope
Cytosol |
| Swissprot ID | O95171 |
| Reactive glutamines | Not determined yet |
| Reactive lysines | Not determined yet |
| Substrate sequence | |
| Structure | No available crystal structure |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:1377656 |
| Notes | |
